Meta-analysis results for all treatments

Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method

Treament Trials      
clinical deteriorationclinical improvementdeathsPCR-negative conversion
chloroquine and derivatives4 1.36 [0.94; 1.97], 1 RCT, I2=0%
inconclusive result
- 1.06 [0.80; 1.41], 2 RCTs, I2=0%
inconclusive result
-
ivermectin3- 1.51 [0.54; 4.24], 1 RCT, I2=0%
inconclusive result
0.29 [0.07; 1.20], 2 RCTs, I2=60%
inconclusive result
OBS 0.52 [0.10; 2.58], 1 study, I2=0%
inconclusive result
azithromycin1 1.36 [0.94; 1.97], 1 RCT, I2=0%
inconclusive result
- 1.08 [0.79; 1.47], 1 RCT, I2=0%
inconclusive result
-
favipiravir 1-- OBS 1.61 [0.73; 3.58], 1 study, I2=0%
inconclusive result
-
lopinavir/ritonavir1- 1.31 [0.94; 1.83], 1 RCT, I2=0%
inconclusive result
0.71 [0.36; 1.40], 1 RCT, I2=0%
inconclusive result
-
remdesivir1- 1.23 [0.87; 1.74], 1 RCT, I2=0%
inconclusive result
1.10 [0.49; 2.45], 1 RCT, I2=0%
inconclusive result
-
ASC09/ritonavir0----
azvudine0----
baloxavir marboxil0----
carrimycin0----
danoprevir / ritonavir0----
darunavir cobicistat0----
darunavir/cobicistat plus chloroquine0----
doxycycline0----
fluvoxamine0----
hydroxychloroquine plus macrolides0----
leronlimab0----
lopinavir / ritonavir plus ribavirin0----
lopinavir/ritonavir plus chloroquine0----
lopinavir/ritonavir plus interferon ß-1a0----
lopinavir/ritonavir, ribavirin and interferon beta-1b0----
meplazumab0----
nitazoxanide0----
oseltamivir0----
oseltamivir plus chloroquin0----
Renin-angiotensin-system-acting agents0----
ribavirin0----
ritonavir0----
sofosbuvir and daclatasvir0----
tenofovir/emtricitabine0----
tenofovir/emtricitabine plus hydroxychloroquine0----
tranexamic acid0----
triazavirin0----
umifenovir (arbidol)0----